Compare HPS & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPS | CLPT |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.8M | 467.9M |
| IPO Year | 2003 | 2009 |
| Metric | HPS | CLPT |
|---|---|---|
| Price | $12.18 | $15.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 123.2K | ★ 550.5K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,971,000.00 |
| Revenue This Year | N/A | $45.67 |
| Revenue Next Year | N/A | $19.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.78 |
| 52 Week Low | $12.04 | $8.27 |
| 52 Week High | $15.68 | $30.10 |
| Indicator | HPS | CLPT |
|---|---|---|
| Relative Strength Index (RSI) | 15.78 | 51.16 |
| Support Level | N/A | $14.65 |
| Resistance Level | $14.66 | $15.29 |
| Average True Range (ATR) | 0.23 | 0.69 |
| MACD | -0.07 | 0.15 |
| Stochastic Oscillator | 3.76 | 48.00 |
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.